Type 1 diabetes mellitus, cystic fibrosis, and congenital hypo­thyroidism are common terms in our medical lexicon. We are well versed in their clinical features, underlying pathophysiology, diagnostic criteria, and management approaches for these three diseases. The same, however, cannot be said for heterozygous familial hypercholesterolemia (hFH). Why is hFH—a potentially fatal disease that has a prevalence rate similar to that of type 1 diabetes and higher than that of cystic fibrosis and congenital hypothyroidism[1,2]—so often not recognized, leaving many affected individuals undiagnosed and untreated? Today, the recently established British Columbia Familial Hypercholesterolemia Registry, the first of its kind in Canada, is attempting to ad­dress this gap in patient care.

Heterozygous familial hypercholesterolemia 
Heterozygous familial hypercholesterolemia is an inherited disorder of lipoprotein metabolism initially des­cribed by Müller in 1938.[3] It has since been named the most common genetic metabolic disease of consequence.[4] An autosomal condition with complete penetrance, hFH affects an estimated 13 million people worldwide;[5] however, less than 25% of these individuals have thus far been identified.[6,7] 

The prevalence of hFH is between 1 in 300 and 1 in 500 in most countries, although it may be as high as 1 in 100 in certain populations—namely those of French Canadian, Christian Lebanese, or  Afrikaner (South Africans of Dutch descent) descent—due to the founder effect.[8,9] Patients with hFH have genetic alterations leading to an impaired hepatic clearance of low-density lipoprotein (LDL) particles.[10] 

Hypercholesterole­mia is present from birth, and untreated individuals have a twentyfold increas­ed risk of premature coronary heart disease (CHD).[8] By age 60, the cumulative risk of fatal or nonfatal CHD is over 50% in males with hFH and 30% in females with hFH.[11,12] Early treatment in the form of lipid-lowering therapy is readily available and highly effective.[10,13,14] In fact, the rate of coronary events in hFH individuals with hFH drops to that of the control population after 10 years of statin therapy.[1,14] By treating three to four patients with hFH, one premature coronary event can be prevented.[15]

The diagnosis of hFH is typically made on clinical and biochemical grounds: a personal or family history of a premature vascular event, and a low-density lipoprotein cholesterol (LDL-C) level above the 95th percentile for age and gender.[6] Tendon xanthomata, often on the Achilles tendon or on the extensor tendons of the hands (or both), are virtually pathognomonic of hFH but are not required for diagnosis.[6] Although premature arcus cor­nealis and xanthelasma may also be present and usually indicate an inherited lipid disorder, they are not specific for hFH.[6,8] 

Several validated diagnostic criteria, such as the MED-PED (make early diagnosis—prevent early death) criteria in the United States,[16] the Simon Broome Register criteria in the United Kingdom,[17] and the Dutch Lipid Clinic Network criteria in the Netherlands,[6] stratify patients according to whether a diagnosis of hFH is “definite,” “probable,” “possible,” or “unlikely.” Demonstration of a functional mutation in the LDL receptor (LDLR) gene, the apolipoprotein B-100 (APOB) gene, or the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene allows for an unequivocal hFH diagnosis, although genetic testing is not mandatory for disease management.[8] 

Because patients with hFH are at considerable risk of early CHD, the 10-year Framingham cardiovascular risk score is inadequate and should not be applied to this patient population.[8,18] Dietary and lifestyle interventions are encouraged and can significantly reduce all-cause morbidity and mortality; these changes, in addition to lifelong lipid-lowering therapy, should be instituted to achieve a minimum of 50% reduction from baseline LDL-C levels.[8,19] The use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) is the cornerstone of treatment,[13,20] while ezetimibe, bile acid sequestrants, and niacin are valuable adjuncts.[8] For patients who experience medication intolerance or are unable to attain therapeutic targets, referral to a specialty lipid or cardiovascular disease prevention clinic is recommended.[8] 

Benefits of disease registries
The US National Committee on Vital and Health Statistics describes disease registries as “an organized system for the collection, storage, retrieval, ana­lysis, and dissemination of information on individual persons who have either a particular disease, a condition (e.g., a risk factor) that predisposes [them] to the occurrence of a health-related event, or prior exposure to substances (or circumstances) known or suspected to cause adverse health effects.”[21] 

Disease registries are a pow­erful tool to engage physicians in the development and adoption of best practices that can lead to improved patient outcomes and reduced health care expenditures.[22] As an example, the Swedish National Hip Registry, established in 1979, led to a 50% reduction in national revision rates by identifying best practices among Swedish orthopaedic surgeons.[23] Estimated cost savings of US$140 million over a 10-year period have been attributed to this decline in revision burden.[24] 

Familial hypercholesterolemia registries in other countries
Nationwide familial hypercholestero­lemia registries have been successfully implemented in Spain, Wales, and the Netherlands.[25-27] Regional programs have been established in Australia, the Czech Republic, Ireland, New Zealand, Norway, the Slovak Republic, Slovenia, and Brazil.[1] In the Netherlands, 1500 to 2000 new cases of hFH are diagnosed each year through the program, with a total of 16 000 affected individuals identified to date.[1] On average, eight new cases of hFH are detected per family, with the initiation of intervention at a mean age of 37 years.[27] 

The participation rate of 98.2%[27] is particularly noteworthy, and reflects a positive patient attitude toward the screening program. 
Cascade, or pedigree, screening is utilized by most programs and has proven to be both economical and effective in reducing CHD and related deaths.[28-30] First-degree relatives of index patients have a 50% likelihood of inheriting hFH, while second- and third-degree relatives have a 25% and  12.5% likelihood of inheriting hFH respectively.[31] Cascade screening entails systematically contacting and identifying af­fected family members, and instituting therapy before the development of clinical atherosclerosis.[30,32]

The registry in British Columbia 
Approximately 68 000 individuals with hFH live in Canada, with about 8000 of these people residing in British Columbia.[33] According to a 1999 World Health Organization re­port, only about 15% of affected Canadians have been properly diagnosed.[6] Among patients identified with the disease, many are not receiving adequate treatment.[6,27]

No hFH screening programs presently exist in Canada, although several lipid clinics have been tracking index patients and their family members. Aside from these lipid clinics, hFH screening is offered by fewer than 10% of cardiologists and family physicians.[6] 

The recently established British Columbia Familial Hypercholestero­lemia Registry has two primary goals: first, to diagnose, educate, and treat individuals with hFH; and second, to disseminate knowledge of this deadly heritable yet highly treatable condition to practising physicians, other health care professionals, and the general public. 

To identify probands currently attending the Healthy Heart Program Prevention Clinic at St. Paul’s Hospital in Vancouver, we have been using the Dutch Lipid Clinic Network criteria (Table 1 [13] and Table 2 [14]).[33,34] The associated sensitivity and specificity for the criteria are outlined in Table 3 [15]; there is an 85% agreement between these criteria and the genet­ically confirmed diagnosis.[34] Not infrequently, individuals with hFH are referred to our clinic only after they experience a major premature vascular event. Once we obtain informed consent, we provide index patients with materials about the registry for their family members, who in turn are encouraged to contact the clinic for evaluation and, if necessary, proper management of hFH. 

In future genetic testing will be offered to all families. This will not only allow for confirmation of hFH, but will almost certainly identify new mutations, as evident from the experiences of other screening programs.[36] Recent work has demonstrated a substantial polygenic contribution to rais­ed LDL-C levels in hFH patients with no known genetic de­fects, a category that accounts for 60% of clinical hFH cases.[37] Thus, novel causal genes may be identified in future, further improving our understanding of hFH disease mechanism and yielding new targets for therapy. 

We anticipate our screening efforts will detect inherited forms of dyslipidemia other than hFH, such as familial combined hyperlipidemia (FCHL). Since individuals with FCHL, like those with hFH, have an increased risk of CHD,[38,39] they too will benefit from lipid-lowering therapy.

The British Columbia Familial Hypercholesterolemia Registry will serve as a model for the rest of Canada. Plans are already underway for similar registries in other provinces, with the ultimate goal of instituting a Canadian familial hypercholesterolemia registry unrestricted by regional boundaries. Such an endeavor will help in our goal of a future in which health care providers and the general public alike are well acquainted with heterozygous familial hypercholesterolemia.

Acknowledgments
We thank Mr Matt Allard and Dr Ramesh Saeedi for reviewing the article.

Competing interests
None declared.

This article has been peer reviewed.

Dr Wong is a University of British Columbia (UBC) medical biochemistry resident. Dr Taraboanta is the clinical coordinator of the British Columbia Familial Hypercholesterolemia Registry and a UBC anatomical pathology resident. Dr Francis is director of the Healthy Heart Program Prevention Clinic, as well as director of the Heart Lung Institute’s Heart and Stroke Foundation of the BC and Yukon Lipid Research Laboratory, both located at St. Paul’s Hospital. He is also a professor of endocrinology and metabolism at UBC. Dr Ignaszewski is head of the Division of Cardiology and is the Physicians Operations Leader—Cardiology at St. Paul’s. He is also a clinical professor of cardiology at UBC. Dr Frohlich is the director of clinical trials at the Healthy Heart Program Prevention Clinic and a professor of pathology and laboratory medicine at UBC. He is also a member of the Health Canada Dyslipidemia Working Group and the Canadian Cardiovascular Risk Assessment Working Group.